Methods	RCT, DB, DD, placebo and active controlled parallel-group study, 12 hour single dose phase, followed by multi-dose phase up to 96 hours for patients with moderate to severe pain
Participants	Post operative total knee or hip arthroplasty surgery Male and females Age 18 to 80 years Mean age 64 years SD 11.0 N = 180
Interventions	Lumiracoxib 400 mg n = 60 Naproxen 500 mg (2 × daily) n = 60 Placebo n = 60
Outcomes	Patients with >50% PR over six hours: lumiracoxib 20/59, dplacebo 11/59 Time to remedication: Lumiracoxib 3.8 hours Placebo 2.0 hours Time to onset: Lumiracoxib 1.5 hours Placebo >12 hours
Notes	QS = 5 (R2, D2, Wl)
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Yes	A - Adequate